Natalizumab and liver injury research information (PubMed) on: October 25, 2019, 07:56:09 pm #1 The Overview section of segment on natalizumab in the report entitled "LiverTox: Clinical and research information on drug-induced liver injury" from the National Institute of Diabetes and Digestive and Kidney Diseases. There is apparently no "likelihood score" (defined as "likely cause of clinically apparent liver injury") included for natalizumab. Natalizumab Natalizumab is a monoclonal antibody to human alpha-4 integrin which has potent immune suppressive activity and is used in the therapy of severe inflammatory bowel disease and relapsing multiple sc... NCBI Bookshelf · ncbi.nlm.nih.gov Last Edit: October 26, 2019, 05:59:43 am by agate Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
